Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 22 for:    "Hemosiderosis" | "Iron Chelating Agents"

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00466063
Recruitment Status : Completed
First Posted : April 27, 2007
Last Update Posted : December 29, 2015
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.

Condition or disease Intervention/treatment
Anemia Drug: Deferasirox

Layout table for study information
Study Type : Observational
Actual Enrollment : 108 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Study Start Date : May 2007
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron
Drug Information available for: Deferasirox

Group/Cohort Intervention/treatment
ICL670
ICL670
Drug: Deferasirox



Primary Outcome Measures :
  1. Safety - renal and hepatic function monitoring. [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: 5 years ]
  2. Longitudinal ferritin levels [ Time Frame: 5 years ]
  3. Assessment of auditory and ophthalmologic status [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
200 unselected children aged from 2 to <6 years at enrolment with chronic iron overload due to repeated blood transfusions. The participating countries were selected on the basis of both a high incidence of young children with thalassemia or other transfusion dependent anemias and on the basis that the drug is approved and 'on the market' in the country selected.
Criteria

Inclusion Criteria:

  • History of transfusion-dependent anemia.
  • History of iron overload

Exclusion Criteria:

  • Patients with non-transfusional hemosiderosis.

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00466063


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
University of South Alabama Medical Center
Mobile, Alabama, United States, 36604
United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Children's Hospital Oakland
Oakland, California, United States, 94609
Children's Hospital of Orange County
Orange, California, United States, 92868-3874
Stanford University Medical Center
Stanford, California, United States, 94304
United States, Florida
MD Anderson Cancer Center - Orlando
Orlando, Florida, United States, 32806
St. Joseph's Children's Hospital of Tampa
Tampa, Florida, United States, 33609
United States, Illinois
Children's Memorial Hospital
Chicago, Illinois, United States, 60614-3394
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
St. Joseph's Children's Hospital
Paterson, New Jersey, United States, 07503
United States, New York
The Brooklyn Hospital Center
Brooklyn, New York, United States, 11201
Schneider Children's Hospital
New York, New York, United States, 11040
SUNY - Upstate Medical University
Syracuse, New York, United States, 13210
United States, North Carolina
East Carolina University
Greenville, North Carolina, United States, 27858
United States, Ohio
Akron Children's Hospital
Akron, Ohio, United States, 44308-1062
Children's Medical Center
Dayton, Ohio, United States, 45404
United States, Oklahoma
Oklahoma State University Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Penn State University / Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033-0850
United States, Tennessee
St. Jude Children's Research Hospital Memphis
Memphis, Tennessee, United States, 38105-2794
United States, Texas
Cook's Children's Medical Center
Fort Worth, Texas, United States, 76104
Texas Children's Hospital
Houston, Texas, United States, 77030
United States, Virginia
Children's Hospital of the King's Daughters
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00466063     History of Changes
Other Study ID Numbers: CICL670A2411
First Posted: April 27, 2007    Key Record Dates
Last Update Posted: December 29, 2015
Last Verified: December 2015
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Iron overload
children
deferasirox
Transfusion-dependent anemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Deferasirox
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action